These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 16266903)

  • 1. Hemostatic balance on the surface of leukemic cells: the role of tissue factor and urokinase plasminogen activator receptor.
    Nadir Y; Katz T; Sarig G; Hoffman R; Oliven A; Rowe JM; Brenner B
    Haematologica; 2005 Nov; 90(11):1549-56. PubMed ID: 16266903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High expression of urokinase plasminogen activator receptor (UPA-R) in acute myeloid leukemia (AML) is associated with worse prognosis.
    Graf M; Reif S; Hecht K; Pelka-Fleischer R; Pfister K; Schmetzer H
    Am J Hematol; 2005 May; 79(1):26-35. PubMed ID: 15849776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct patterns of urokinase receptor (uPAR) expression by leukemic cells and peripheral blood cells.
    Jardí M; Inglés-Esteve J; Burgal M; Azqueta C; Velasco F; López-Pedrera C; Miles LA; Félez J
    Thromb Haemost; 1996 Dec; 76(6):1009-19. PubMed ID: 8972026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue factor (TF) and urokinase plasminogen activator receptor (uPAR) and bleeding complications in leukemic patients.
    López-Pedrera C; Jardí M; del Mar Malagón M; Inglés-Esteve J; Dorado G; Torres A; Félez J; Velasco F
    Thromb Haemost; 1997 Jan; 77(1):62-70. PubMed ID: 9031451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy.
    Mustjoki S; Alitalo R; Stephens RW; Vaheri A
    Thromb Haemost; 1999 May; 81(5):705-10. PubMed ID: 10365741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arsenic trioxide downregulates the expression of annexin II in bone marrow cells from patients with acute myelogenous leukemia.
    Zhang XH; Hu Y; Bao L; Jiang Q; Yang LH; Lu XJ; Hong M; Xia LH; Guo T; Shen GX; Zhu HH; Zhao T; Song SJ
    Chin Med J (Engl); 2009 Sep; 122(17):1969-73. PubMed ID: 19781379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Membrane and intracellular platelet-activating factor receptor expression in leukemic blasts of patients with acute myeloid and lymphoid leukemia.
    Donnard M; Guglielmi L; Turlure P; Piguet C; Couraud MJ; Bordessoule D; Denizot Y
    Stem Cells; 2002; 20(5):394-401. PubMed ID: 12351810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urokinase plasminogen activator receptor and soluble matrix metalloproteinase-9 in acute myeloid leukemia patients: a possible relation to disease invasion.
    Aref S; El-Sherbiny M; Mabed M; Menessy A; El-Refaei M
    Hematology; 2003 Dec; 8(6):385-91. PubMed ID: 14668033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flow cytometry evaluation of urokinase-type plasminogen activator receptor (UPA-R) in acute myeloid leukemia cells.
    Castagnari B; Moretti S; Latorraca A; Rigolin GM; Balsamo R; Lanza F; Castoldi GL
    Boll Soc Ital Biol Sper; 1995; 71(5-6):141-7. PubMed ID: 8519488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of poliovirus receptor-related proteins PRR1 and PRR2 in acute myeloid leukemia: first report of surface marker analysis, contribution to diagnosis, prognosis and implications for future therapeutical strategies.
    Graf M; Reif S; Hecht K; Kroell T; Nuessler V; Schmetzer H
    Eur J Haematol; 2005 Dec; 75(6):477-84. PubMed ID: 16313259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis of acute myeloid leukemia and system Coulter VCS.
    Bruno A; Del Poeta G; Venditti A; Stasi R; Adorno G; Aronica G; Suppo G; Di Rienzo AM; Iazzoni R; Tribalto M
    Haematologica; 1994; 79(5):420-8. PubMed ID: 7843628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid enzymes profile related to the immunophenotypic characteristics of blast cells from patients with acute myeloid leukemia (AML) at diagnosis.
    Klobusicka M; Kusenda J; Babusikova O
    Neoplasma; 2005; 52(3):211-8. PubMed ID: 15875082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
    Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
    Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased urokinase-type plasminogen activator receptor and epidermal growth factor receptor in serum of patients with prostate cancer.
    Milanese G; Dellabella M; Fazioli F; Pierpaoli E; Polito M; Siednius N; Montironi R; Blasi F; Muzzonigro G
    J Urol; 2009 Mar; 181(3):1393-400. PubMed ID: 19157433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor for platelet-activating factor (PAF) is not detectable by flow cytometry on the surface of myeloid leukemic cells.
    Berdel WE; Kulimova E; Kolkmeyer A; Zühlsdorf M; Serve H; Büchner T; Oelmann E
    Ann Hematol; 2005 Nov; 84(12):771-3. PubMed ID: 16094532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
    Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
    Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients].
    Zhou Q; Liang LJ; Peng BG; Zhen YY
    Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative expression of Toll-like receptor-2, -4, and -9 in dendritic cells generated from blasts of patients with acute myeloid leukemia.
    Schmitt A; Li L; Giannopoulos K; Greiner J; Reinhardt P; Wiesneth M; Schmitt M
    Transfusion; 2008 May; 48(5):861-70. PubMed ID: 18208411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
    Zhou H; Wu X; Lu X; Chen G; Ye X; Huang J
    Thromb Res; 2009; 123(3):537-42. PubMed ID: 18691743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia.
    Tsai DE; Luger SM; Andreadis C; Vogl DT; Kemner A; Potuzak M; Goradia A; Loren AW; Perl AE; Schuster SJ; Porter DL; Stadtmauer EA; Goldstein SC; Thompson JE; Swider C; Bagg A; Mato AR; Carroll M
    Clin Cancer Res; 2008 Sep; 14(17):5619-25. PubMed ID: 18765556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.